Arthur Becker was born in Brooklyn, New York. After his studies at Bennington College in 1972, Arthur ventured in investment projects. Based in New York, Arthur is an entrepreneur, an artist, philanthropist, and an investor. Arthur is currently working in real estate, biotechnology, and information technology. Arthur Becker also has an interest in fashion and art.
Arthur has worked for various companies. He first worked at Navisite Atlantic Investors, a company that provided internet technology to businesses in United States and United Kingdom. Navisite was later sold to Times Warner in 2011. At Zinio LLC, Arthur was the Chairman and the Chief Executive Officer of the world’s largest digital magazine distributor. He also worked for Vera Wang Fashion Company as an advisor for seven years.
Arthur Becker is now the Managing Member of Madison Partners. Madison Partners is a firm that focuses on real estate and early stage biotechnology ventures. While at Zinio, Arthur was engaged in real estate and technology. Due to this engagement, he expanded his interests in real estate by investing in the development of condominium. Arthur is also fascinated by early stage biotechnology for its potential to impact lives positively.
In 2011, Arthur started to invest privately in real estate and technology companies through Madison Partners. Arthur is currently the owner of three townhouses located on Sullivan Street in Soho. It is approximated that he bought the houses at $15 million plus $5 million for mortgages as shown by Real Capital Analytics.
Besides real estate, Arthur also has an interest in biotech. His interest for biotech emanates from his belief that it has a potential to impact lives positively. In biotechnology, his interest is in the field of cancer treatment.
Arthur’s love to work for people is what makes him exceptionally effective. Madison Partners has been ahead of other companies because of the lessons learned from Arthur’s many failed attempts to make a difference in society.
Madison Partners has some partners in biotech fields. C4 Therapeutics is a company whose products degrade disease-relevant proteins for therapeutic benefit. OncoPep is also a biotechnology company that produce products that prevent the progression of cancer. Other companies are Acetylon Pharmaceuticals, Regenacy Pharmaceuticals, and Frequency Therapeutics. TO learn more, visit arthurbeckerstudio.com.